Olema Pharmaceuticals, Inc.

Transaction Overview:

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”) (the “Company”) (Nasdaq:OLMA), priced its $209 million initial public offering on November 18, 2020 at a price of $19 per share. The Company issued 11,000,000 shares of common stock. The Underwriters exercised their option to purchase an additional 1,650,000 shares of common stock at the initial public offering price, bringing the total proceeds to $240.4 million, less the underwriting discounts and commissions.

Company Overview:

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer.